Yahoo Finance Insider Sale: Director Lee Newcomer Sells 6,200 Shares of Myriad Genetics Inc (MYGN)
On May 13, 2024, Director Lee Newcomer sold 6,200 shares of Myriad Genetics Inc (NASDAQ:MYGN) as reported in a recent SEC Filing. The transaction occurred at a price of $25.3 per share.
Myriad Genetics Inc, a company specializing in molecular diagnostics and personalized medicine, focuses on transforming patient care through the discovery and commercialization of transformative tests to assess the risk of developing disease, or the risks associated with a particular disease, and guide treatment decisions across medical specialties.
Following this transaction, the insider transaction history for Myriad Genetics Inc shows a trend of more sales than purchases among insiders over the past year. There have been zero insider buys and five insider sells in the last twelve months.
The sale by the insider has occurred at a time when the stock is considered Fairly Valued according to the GF Value of $23.38, with a price-to-GF-Value ratio of 1.08. The GF Value is a proprietary measure used to determine the fair value of a stock based on historical trading multiples, an adjustment factor based on past performance, and future business performance estimates.
As of the latest trading price, Myriad Genetics Inc has a market cap of approximately $2.23 billion. The company's valuation metrics, including the price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, are essential in understanding the stock's current trading state and future potential.
Overall, the recent insider activity and valuation metrics provide a snapshot of Myriad Genetics Inc's current market position and insider sentiment. Investors and stakeholders continue to monitor these trends for insights into the company's operational and market performance.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
